A microplate indicator-based method for determining the susceptibility of multidrug-resistant Mycobacterium tuberculosis to antimicrobial agents

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 2, 2004, Pages 253-259

  Morcillo, Nora ^a   Di Giulio, B ^b   Testani, B ^a   Pontino, M ^a   Chirico, C ^c   Dolmann, A ^d  

^a Ref Lab Buenos Aires TB Contr P   (Argentina)

^b Petrona V de Cordero Hospital   (Argentina)

^c Reg Tuberculosis Control Program   (Argentina)

^d Hospital Zonal de Agudos y Cronicos Dr Antonio A Cetrangolo   (Argentina)

Author keywords

Colorimetric microtiter based method; Multidrug resistant tuberculosis; Second line drugs

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; INDICATOR; KANAMYCIN; LEVOFLOXACIN; RIFABUTIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARGENTINA; ARTICLE; BACTERIUM ISOLATE; CELL GROWTH; CELL VIABILITY; COLORIMETRY; COST UTILITY ANALYSIS; DILUTION; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PRIORITY JOURNAL; STANDARD;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DYE DILUTION TECHNIQUE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TETRAZOLIUM SALTS; THIAZOLES; TITRIMETRY; TUBERCULOSIS, PULMONARY;

EID: 2442539087     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. World Health Organization. Anti-tuberculosis Drug Resistance in the World. Report No 2. Prevalence and Trends: The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997. WHO/CDS/TB/2000.278. Geneva: WHO, 2000.
2. Dooley S W, Jarvis W R, Marlone W, Snider D E. Multidrug-resistant tuberculosis. Ann Intern Med 1992; 117: 257-259.
3. Herrera D, Cano R, Godoy P, et al. Multidrug-resistant tuberculosis outbreak on an HIV-ward Madrid, MMWR 1996; 45: 330-333.
4. Ritacco V, Di Lonardo M, Reniero A, et al. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J Clin Infect Dis 1997; 176: 167-172.
5. Morcillo N, Cordero G, Davenport S, Di Giulio B, Dolmann A. In vitro activity of several drugs against Mycobacterium tuberculosis using an economical and rapid microplate colorimetric method. Int J Tuberc Lung Dis 2001; 5 (Suppl): S189.
6. Goods G L. Susceptibility testing for mycobacteria. Clin Infect Dis 2000; 29: 1209-1215.
7. Canetti G, Fox W, Khomenko A, Mahler H T, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programs. Bull World Health Organization 1969; 41: 21-43.
8. Heifets L B. Drugs susceptibility tests in the management of chemotherapy of tuberculosis, Chapter 3, 89-121. In: Heifets L B, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991.
9. Thom S M, Horobin RW, Seidler E, Barrer M R. Factors affecting the selection and use of tetrazolium salts as cytochemical indicators of microbial viability and activity. J Appl Bacteriol 1993; 74: 433-443.
10. Yajko D, Madej J, Lancaster M V, et al. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol 1995; 33: 2324-2327.
11. Collins L A, Franzblau S G. Microplate alamar blue assay versus BACTEC460 System for high-throughput screening of compounds against Mycobacterim tuberculosis and M. avium. Int J Tuberc Lung Dis 1997; 41: 1004-1009.
12. Mshana R N, Tadesse G, Abate G, Miorner H. Use of 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant Mycobacterium tuberculosis. J Clin Microbiol 1998; 36: 1214-1219.
13. Abate G, Mshana R N, Miorner H. Evaluation of colorimetric assay based on 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1998; 2: 1011-1016.
14. McNeil B J, Hanley J A. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making 1984; 4: 137-150.
15. Van Der Schouw I T, Verbeek A I M, Ruijs S H J. Guidelines for the assessment of new diagnostic tests. Investigative Radiology 1995; 30: 334-340.
16. Heifets L B. Conventional methods for antimicrobial susceptibility testing of M. tuberculosis. In: Bastian I, Portaels F. Multidrug-resistant tuberculosis. London, UK: Kluwer Academic Publishers, 2001: pp 135-136.
17. United Nations University (UNU) and Latin American and the Caribbean Network of Tuberculosis (RELACTB). New technologies for diagnosis and drug-susceptibility testing of M. tuberculosis for developing countries. La Paz, Bolivia: Institute of National Laboratories of Health (INLASA), 1998: pp 24-32.
18. Toman K. Sensitivity, specificity and predictive values of diagnostic tests. Bull Int Union Tuberc 1981; 56: 18-30.
19. Farmer P, Kim J Y. Community based approaches to the control of multidrug-resistant tuberculosis: introducing "DOTS-plus". N Engl J Med 1998; 344: 1294-1303.
20. Iseman M D. MDR-TB and the developing world-a problem no longer to be ignored: the WHO announces "DOTS Plus" strategy. Int J Tuberc Lung Dis 1998; 2: 867-868.
21. Gupta R, Espinal M A, Jaramillo E, Raviglioni M C. Management of MDR-TB in resource-limited countries. Int J Tuberc Lung Dis 2002; 6 (Suppl 1): S28.
22. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
23. Mitchison D A. How drug resistance emerges as a result of poor compliance during short course of chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
24. McClatchy J K. Susceptibility testing of mycobacteria. Lab Med 1978; 9: 47-52.
25. Jorgensen J H, Ferraro M J. Antimicrobial susceptibility testing: General principles and contemporary practices. Clin Infect Dis 1997; 26: 973-980.
26. Gomez-Flores R, Gupta S, Tamez-Guerra R, Mehta T. Determination of MICs for Mycobacterium avium-intracellulare complex in liquid medium by a colorimetric method. J Clin Microbiol 1995; 33: 1842-1846.
27. Palomino J C, Martin A, Camacho M, Guerra H, Swings J, Portaels F. Resarzurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicr Agents Chemother 2002; 46: 2720-2722.
28. Foongladda S, Roengsantia D, Arjrattanakool W, Chuchottaworn C, Chaiprasert A, Franzblau S. Rapid and simple MTT method for rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2003; 6: 1118-1122.
29. Conte J, Golden J A, Duncan S, McKenna E, Zurlinden E. Intrapulmonary pharmacokinetics of clarithromycin and erithromycin. Antimicr Agents Chemother 1995; 39: 334-338.
30. Iseman M D. Synergism: the Rosetta stone for Mycobacterium avium complex chemotherapy? Am Rev Respir Dis 1998; 138: 767-768.
31. Morcillo N, Scipioni S, Poggio G, de Kantor I N. In vitro activity of several drug combinations against multidrug-resistant Mycobacterium tuberculosis (MDR-TB) and M. avium complex (MAC) strains. Tubercle Lung Dis 1996; 77 (Suppl 2): s126.
32. Felmlee T, Quiang L, Whelen A C, Williams D, Sommer S S, Persing D H. Genotypic detection of Mycobacterium tuberculosis rifampin resistance: comparison of single-strand conformation polymorphism and dideoxy fingerprinting. J Clin Microbiol 1995; 33: 1617-1623.
33. Uzun M, Erturan Z, Ang O. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 2002; 6: 164-165.
34. Nachega, J B, Chaisson R E. Tuberculosis drug resistance: a global threat. CID 2003; 36: S24-S30.
35. Luna Herrera J, Martinez Cabrera G, Parra Maldonado R, et al. Use of receiver operating characteristic curves to assess the performance of microdilution assay for determination of drug susceptibility of clinical isolates of Mycobacterium tuberculosis. J Clin Microbiol Infect Dis 2003; 22: 21-27.
36. Kent P T, Kubica G P. Public Health Mycobacteriology. A guide for the level III Laboratory. Atlanta, GA: Centers for Disease Control, 1985.
37. World Health Organization. The containment laboratory-biosafety level 3. Laboratory biosafety manual. 2nd ed. Geneva, Switzerland: WHO, 1993: pp 19-23.